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Abstract
Background: Obstetric-related acute kidney injury (AKI) is thought to be a key contributor to the overall burden of
AKI in low resource settings, causing significant and preventable morbidity and mortality. However, epidemiological
data to corroborate these hypotheses is sparse. This prospective observational study aims to determine the incidence,
aetiology and maternal-fetal outcomes of obstetric-related AKI in Malawi.
Methods: Women greater than 20 weeks gestation or less than 6 weeks postpartum admitted to obstetric wards at a
tertiary hospital in Blantyre, Malawi, and at high-risk of AKI were recruited between 21st September and 11th
December 2015. All participants had serum creatinine tested at enrolment; those with creatinine above normal range
(> 82 μmol/L) underwent serial measurement, investigations to determine cause of kidney injury, and were managed
by obstetric and nephrology teams. AKI was diagnosed and staged by Kidney Disease Improving Global Outcomes
(KDIGO) criteria. Primary outcomes were the incidence proportion and aetiology of AKI. Secondary outcomes were
in-hospital maternal mortality, need for dialysis, renal recovery and length of stay; in-hospital perinatal mortality,
gestational age at delivery, birthweight and Apgar score.
Results: 354 patients were identified at risk of AKI from the approximate 2300 deliveries that occurred during the
study period. Three hundred twenty-two were enrolled and 26 (8.1%) had AKI (median age 27 years; HIV 3.9%).
The most common primary causes of AKI were preeclampsia/eclampsia (n = 19, 73.1%), antepartum haemorrhage
(n = 3, 11.5%), and sepsis (n = 3, 11.5%). There was an association between preeclampsia spectrum and AKI (12.2%
AKI incidence in preeclampsia spectrum vs. 4.3% in other patients, p = 0.015). No women with AKI died or required
dialysis and complete renal recovery occurred in 22 (84.6%) cases. The perinatal mortality rate across all high-risk
admissions was 13.8%. AKI did not impact on maternal or fetal outcomes.
Conclusions: The incidence of AKI in high-risk obstetric admissions in Malawi is 8.1% and preeclampsia was the
commonest cause. With tertiary nephrology and obstetric care the majority of AKI resolved with no effect on
maternal-fetal outcomes. Maternal-fetal outcomes in Sub-Saharan Africa may be improved with earlier detection
of hypertensive disease in pregnancy.
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Background
Acute Kidney Injury (AKI) in pregnancy causes signifi-
cant morbidity and mortality [1, 2]. It is increasingly
recognised as a condition that is both preventable and
treatable, often with simple and inexpensive interven-
tions [3]. In developed countries, the incidence of AKI
in pregnancy has been dramatically reduced as a result
of improving clinical care [4]; a recent Canadian study
found an AKI rate of 2.68 per 10,000 deliveries [5]. In
developing countries, AKI in pregnancy is more com-
mon though less well studied, with AKI rates of 66 per
10,000 deliveries, for example, reported in Morocco [6].
The International Society of Nephrology recently
launched the 0by25 initiative, which aims to eliminate
preventable deaths from AKI by 2025 [7]. An initial goal
is to establish the global burden of AKI, particularly in
low-income settings. Over 50% of global maternal deaths
occur in Sub-Saharan Africa (SSA), but the contribution
of kidney disease to these is unknown [8]. Only three
studies investigating AKI in pregnancy from SSA have
been published since 1990; these report AKI limited to
dialysis units, intensive care and women with severe pre-
eclampsia [9–11]. In these studies, the predominant
causes of AKI were preeclampsia-eclampsia, haemor-
rhage and sepsis.
To the best of our knowledge, there are no previous
studies investigating obstetric AKI outside intensive care
and dialysis units in SSA; the causes and consequences
of AKI for mother and fetus are unknown. This study
aimed to determine the incidence proportion, aetiology
and maternal-fetal outcomes of AKI in obstetric patients
at high-risk for AKI admitted to a tertiary hospital in
Malawi. In a population with a high fertility rate (mean
5 births per woman in SSA [12]) and high prevalence of
preeclampsia, sepsis and haemorrhage [13], we predicted
a high rate of obstetric-related AKI, leading to adverse
outcomes for mother and fetus.
Methods
Study setting and design
We conducted a prospective observational study be-
tween 21st September and 11th December 2015 in the
Obstetrics and Gynaecology Department of Queen Eliza-
beth Central Hospital (QECH), Blantyre, Malawi. This
unit delivers approximately 12,000 women per year and
receives tertiary referrals from across the southern re-
gion of the country, although the majority of admissions
are from within Blantyre district itself.
Inclusion and exclusion criteria
All women aged 16 years and older, and greater than
20 weeks gestation or less than six weeks postpartum ad-
mitted to the Obstetric High Dependency Unit or high-
risk areas of labour/antenatal/postnatal/gynaecology
wards were assessed for risk of AKI within 48 h of admis-
sion. Presentation with one of 8 conditions was considered
to place women at increased risk of AKI: gestational
hypertension, preeclampsia, eclampsia, antepartum haem-
orrhage, postpartum haemorrhage, sepsis, heart failure
and renal failure (Table 1). Patients with known renal fail-
ure were defined as a pre-existing diagnosis of CKD, or
because a urea/creatinine result had already been obtained
by the obstetric team and was elevated.
Study recruiters assessed whether AKI risk factor defi-
nitions were met; where insufficient information was
documented to support or refute the presence of a risk
factor, the treating obstetrician’s clinical diagnosis was
used. All women at increased risk of AKI were enrolled
in the study, baseline clinical data were recorded, and
screening serum creatinine (SCr) was measured to deter-
mine the presence/absence of kidney disease. Screening
SCr > 82 μmol/L was considered to be elevated, deter-
mined prospectively as being two standard deviations
above mean SCr in the third trimester of pregnancy [14].
Women with elevated SCr on admission (> 82 μmol/L)
were followed up with daily measurement of SCr and
urine output, in addition to detailed clinical assessment
and management by both the nephrology and obstetric
teams. We recorded the nature and most likely causes of
renal impairment based on the assessment of all avail-
able clinical and laboratory investigations as well as de-
tails of management thereafter. Patients with normal
SCr (< 82 μmol/L) at enrolment were managed by obste-
tricians and not routinely seen by the study team. The
development of AKI in hospital was not assessed.
Maternal and fetal outcomes, identified from ward dis-
charge and delivery records as well as individual patient
records, were recorded in all women. Hospital maternal
mortality records were crosschecked to ensure that no
Table 1 Study inclusion criteria and definitions
Inclusion criterion Definition
Gestational hypertension New onset hypertension after 20 weeks
gestation (defined as two BP readings >
140/90 separated by ≥4 h)
Preeclampsia Gestational hypertension with dipstick
proteinuria ≥1+
Eclampsia Seizure with preeclampsia
Sepsis Treating clinician’s judgement
Antepartum haemorrhage Any documented vaginal bleeding except
“spotting”
Postpartum haemorrhage Any documented bleeding considered by
the treating obstetrician not to be
physiological
Heart failure Pre-existing clinical diagnosis
Renal failure Pre-existing clinical diagnosis
Definitions for hypertensive diseases from American College of Obstetricians
and Gynecologists [23]
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women lost to follow-up had died. Women were
followed up until death, discharge, or a predefined
period of 2 weeks after last recruitment.
Creatinine measurement
Serum creatinine (SCr) was tested (Jaffe method) using
either a Flexor Junior Clinical Chemistry Analyser [Vital
Scientific, The Netherlands] (31% samples) or Mindray
Chemistry Analyzer BS-120 [Shenzen Mindray Bio-
Medical Electronics Company, China] (69% samples).
Biochemistry analysers were calibrated in accordance
with the manufacturer’s instructions. A second analyser
was used due to unresolvable technical problems with
the original machine during part of the study.
Definitions
AKI was diagnosed and staged according to Kidney Dis-
ease: Improving Global Outcomes (KDIGO) criteria [15]
(Additional file 1). The lowest SCr recorded during ad-
mission or in the 3 months prior to admission was used
as the baseline value. Imputed baselines based on a pre-
sumed normal Glomerular Filtration Rate (GFR) were
not used in cases where the baseline was unknown.
Women with evidence of renal impairment (SCr >
82 μmol/L) which was thought to be of less than
3 months duration but who did not fulfil KDIGO AKI
criteria were categorised as having an Acute Kidney Dis-
order (AKD) and were not included in any further ana-
lysis. Women with renal impairment of greater than
3 months duration were diagnosed with Chronic Kidney
Disease (CKD) as per KDIGO and were not included in
any further analysis [15]. AKI aetiology was determined,
after detailed clinical review of each case, by a panel of
clinicians led by a nephrologist (UH).
Complete renal recovery was defined as final measured
SCr < 82 μmol/L after an initial SCr > 82 μmol/L. Where
mothers remained in hospital solely because their child
was receiving neonatal care or were transferred to pri-
vate wards, maternal length of stay data were considered
to be unrepresentative of maternal outcomes and were
excluded from the analysis.
Perinatal mortality was defined as fetal death after
20 weeks gestation (stillbirth or termination of preg-
nancy) or neonatal death before discharge from hospital
(early or late neonatal death). Preeclampsia spectrum
was defined as gestational hypertension, preeclampsia or
eclampsia.
Outcomes
Primary outcome measures were the incidence propor-
tion and aetiology of AKI. Secondary outcomes were
maternal survival, need for maternal dialysis, renal re-
covery and maternal length of stay; fetal survival,
gestational age at delivery, birthweight and Apgar score
at 1 min after delivery [16].
Statistical analyses
We conducted a descriptive analysis of the study cohort.
Variables are reported as mean ± standard deviation (SD)
or median ± inter-quartile range (IQR) depending on
their distribution. We compared variables between
women with NKD and any stage of AKI using the Stu-
dent’s t test if normally distributed, the Mann-Whitney
U test if not normally distributed and Chi-squared or
Fisher’s exact test for proportions. Statistical analysis
was performed using STATA version 10 (www.stata.-
com). A p value of < 0.05 was considered to represent
statistical significance.
Results
Study recruitment is summarised in Fig. 1. Two thou-
sand two hundred forty-six women delivered during the
study recruitment period.
Baseline data




AKI of any stage was identified in 26 (8.1%) recruited
women (Fig. 1). 12 (46.2%) cases of AKI were stage 1 [me-
dian screening SCr 99 μmol/L, IQR 94 – 118]; 8 (30.8%)
cases were stage 2 [median screening SCr 99 μmol/L, IQR
96 – 120], and 6 (23.1%) cases were stage 3 [median
screening SCr 139 μmol/L, IQR 135 – 148].
Aetiology of AKI
The primary causes of AKI were preeclampsia/eclampsia
(n = 19, 73.1%), antepartum haemorrhage (n = 3, 11.5%),
sepsis (n = 3, 11.5%) and cardiac failure (n = 1, 3.8%).
The sources of sepsis were endometritis, chorioamnioni-
tis and Bartholin’s abscess. In 13 (50%) cases, multiple
factors contributed to development of AKI; nephrotoxins
(NSAIDs, tenofovir, gentamicin or traditional medica-
tions) were a contributing factor in 10 (38.5%) cases.
Secondary outcomes
Maternal outcomes were determined in 254 (84.1%)
women. Two women died during their inpatient stay, nei-
ther had renal impairment. No woman required acute dia-
lysis for AKI during her admission. Complete renal
recovery occurred within 7 days in 22 (84.6%) AKI cases
overall (75% of stage 1, 87.5% of stage 2 and 100% of stage
3 AKI). The remaining women (n = 4, 15.4%) were dis-
charged before their creatinine fell below 82 μmol/L; three
had evidence of partial renal recovery prior to discharge
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(discharge SCr was 84, 98, and 106 μmol/L); one had no
renal recovery with discharge SCr 186 μmol/L.
Maternal length of stay was assessed in 234/302
(77.5%) cases: 16 mothers remained in hospital solely be-
cause their child was receiving neonatal care, 4 were
transferred to private wards, 3 remained in hospital at
the end of follow-up, and 45 were lost to follow-up. Me-
dian length of stay in women with NKD was 7 days
(IQR 5 – 9) compared to 7 days (IQR 5 – 9) in women
with AKI (p = 0.42).
Fetal outcomes were determined in 271/302 (89.7%)
cases, 1 was lost to follow-up, and 30 were recruited
Eligible patients with 
one or more risk factors 
for AKI (n = 354)
Subjects recruited
(n = 322)
Not recruited: refusal, 
inability to consent, 
inability to process 
creatinine sample
(n = 32)
No Kidney Disease (NKD)
Screening serum 




















Stage 1: n= 12 (46.2%)
Stage 2: n = 8 (30.8%)
Stage 3: n = 6 (23.1%)
Daily measurement of 
serum creatinine
Fig. 1 Flow chart of inclusion in the study
Cooke et al. BMC Nephrology  (2018) 19:25 Page 4 of 8
antenatally and discharged prior to delivery. Fetal out-
comes in patients with AKI and NKD are shown in
Table 3. There were no statistically significant differences
in any fetal outcome between AKI and NKD cohorts;
median Apgar score at 1 min was lower in the AKI co-
hort (6) than in the NKD cohort (8), this approached
statistical significance (p = 0.06).
Perinatal death occurred in 37/269 (13.8%) cases
overall, regardless of renal impairment. One of the
four perinatal deaths in AKI patients was a stillbirth
at 30 weeks (in a mother with preeclampsia and
APH, recruited at 3 days postpartum) suggesting fetal
death likely preceded onset of AKI. The other three
were early neonatal deaths: one mother with pre-
eclampsia was recruited antenatally and delivered at
30 weeks; one delivered at 40 weeks and was re-
cruited 2 days postpartum with endometritis; one de-
livered at 29 weeks with preeclampsia and sepsis and
was recruited 2 days postpartum.
There was an association between preeclampsia
spectrum (gestational hypertension, preeclampsia or
eclampsia) and AKI. 20/164 (12.2%) women recruited
with preeclampsia spectrum had AKI; 6/138 (4.3%)




To the best of our knowledge, this is the first study to
prospectively investigate obstetric-related AKI outside
intensive care and dialysis units in Sub-Saharan Africa.
8.1% of the cohort had AKI and the most common pri-
mary cause of AKI was preeclampsia spectrum, with a
smaller contribution from sepsis and antepartum haem-
orrhage. No women with AKI died or required dialysis
and the majority of AKI cases had complete renal recov-
ery, even in stage 3 AKI. Fetal outcomes overall were
poor with high rates of perinatal death. There were no
statistically significant differences between AKI and
NKD cohorts in either maternal or fetal outcomes.
We have identified ten publications investigating AKI
in pregnancy from all of Africa since 1990 (Add-
itional file 2). Three of these studies are from SSA; one
investigates ICU patients [10], one investigates dialysis
patients [9], and the other only includes patients with se-
vere preeclampsia or eclampsia [11]. AKI prevalence
amongst ICU patients varied from 6 to 34% and the
commonest causes of AKI reported were preeclampsia-
eclampsia, haemorrhage and sepsis.
A recent population-wide study from Canada reported
an AKI incidence rate of 2.68 per 10,000 deliveries, with
aetiologies similar to the previous African studies [5].
This study found AKI in 26 (8.1%) recruited women;
given 2246 deliveries during the study period, we calcu-
late the minimum incidence rate of AKI to be 116 per
10,000 deliveries in Malawi (over 40 times greater than
the Canadian study). We have a novel cohort for SSA
and cannot directly compare our AKI rate to that of pre-
vious ICU studies from the same region.
Whilst a recent review suggests sepsis and hypovol-
aemia are predominant causes of obstetric-related AKI
in developing countries [1], our findings are consistent
with those from other studies from Africa and match
the patterns found in developed countries: preeclampsia-
eclampsia underlies the majority of AKI. The association
between preeclampsia spectrum at recruitment and AKI
supports this. Table 4 demonstrates conditions contrib-
uting to the development of AKI in our cohort, as com-
pared to data from Canada in 2007–10 [5]. Though the
Canadian data define AKI based on clinician diagnosis
as opposed to KDIGO criteria, there is an interesting
comparison in AKI aetiology. Of note, there is a greater
contribution of preeclampsia-eclampsia patients and a
lesser contribution of postpartum haemorrhage to the
development of AKI in our cohort.
Maternal outcomes in women with AKI were better
than expected: no woman with AKI died or required dia-
lysis. This may be accounted for by the quality of care in
QECH, a tertiary centre with doctors providing care,
regular monitoring, and some access to blood tests and
Table 2 Baseline data of women with acute kidney injury (AKI)
and no kidney disease (NKD)
NKD (n = 276) AKI (n = 26) p value
Age in years 25 (20–30) 27 (20–32) 0.44
Gravidity 2 (1–4) 2 (1–3) 0.43
Previous pregnancy loss 70 (25.4) 5 (19.2) 0.49
HIV positive 33 (12.0) 1 (3.9) 0.43
Antiretroviral therapy (prior
to recruitment)
29 (10.5) 1 (3.9) 0.28
Diabetes as co-morbidity 1 (0.36) 0 (0) 0.76
Any nephrotoxinsa (prior to
recruitment)
99 (36.0) 8 (30.8) 0.60
Figures shown are median (interquartile range) or frequency (%)
aNephrotoxins = NSAIDs, tenofovir, gentamicin or traditional medications;
recorded if taken within 1 week of recruitment
Table 3 Fetal outcomes in patients with acute kidney injury
(AKI) no kidney disease (NKD)
NKD (n = 276) AKI (n = 26) p value
Gestational age in weeks
(median; IQR)
37.7 (35.0–39.3) 37.6 (30.7–39.4) 0.56
Perinatal death (n; %) 33 (13.6) 4 (15.4) 0.8
Fetal weight in kg
(median; IQR)
2.8 (2.2–3.3) 2.5 (1.6–3.3) 0.26
Apgar score (median; IQR) 8 (5.0–8.0) 6 (4.0–8.0) 0.06
Figures shown are median (interquartile range) or frequency (%)
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medications. Renal impairment was detected early and
women were managed jointly by nephrologists and ob-
stetricians, a level of care which is not universal across
SSA.
Strengths and limitations
This study reports data from a new population: obstetric
ward admissions at high-risk of AKI in SSA. It comple-
ments previous studies looking at ICU and dialysis pa-
tients, providing data on less apparently unwell patients.
Malawi provides a unique context to perform this study
in SSA. Free access to healthcare means the sample se-
lected and the care provided for these women was not
confounded by their ability to pay for care. Moreover,
whilst QECH is a tertiary healthcare facility, it also acts
as the district hospital for Blantyre and the majority of
admissions represent provision of secondary care to the
local population, making the study more generalisable
for the country as a whole.
The study was performed in a challenging context
where access to investigations is limited. Practical issues
(e.g. lack of urine measuring jugs, lack of catheter bags
with graduations to accurately measure urine volume)
made collecting data on urine output difficult. We were
unable (logistically and financially) to measure SCr in all
patients who delivered due to the number of deliveries
that occur at this centre, and some of these patients may
have had kidney injury leading us to underestimate true
incidence of AKI. Similarly, we could not undertake ser-
ial SCr in every recruited woman, so used a single
screening SCr to identify patients at risk of AKI, which
we then targeted with serial SCr measurement. We
chose to use a threshold which is 2 standard deviations
above the mean in the third trimester, which may not be
representative of this African population: as stated, some
patients with screening creatinine < 82 μmol/L may have
had AKI, especially those with lower BMI. Nevertheless
this is a lower threshold than other comparable studies
from SSA (a study from Cameroon defined renal failure
as creatinine > 97 μmol/L, a South African study as cre-
atinine > 100 μmol/L [10, 11]) and highlights the chal-
lenges of diagnosing kidney disease in pregnancy more
generally. Importantly, we only used this value to screen
patients for kidney disease at recruitment, and AKI was
confirmed on serial creatinine and urine output meas-
urement thereafter and diagnosed according to the
KDIGO criteria described. Serial SCr was not measured
in women with a normal screening SCr and therefore
hospital-acquired AKI was not assessed, although the
majority of AKI in SSA is thought to be community ac-
quired [17, 18].
Baseline data were recorded from the treating clini-
cian’s notes, which may have been inaccurate. It was not
possible to obtain urine dipstick results from all re-
cruited patients. The small study size and possible
underestimation of AKI may mean some true associa-
tions between AKI and maternal-fetal outcomes were
not identified. The study was performed outside malaria
season, one of the commonest causes of AKI in Malawi
[18], and the pattern of AKI may be different at other
times of the year.
Care provided to study participants at QECH might
not be considered representative of care across SSA. The
presence of an obstetrician-staffed Obstetric High De-
pendency Unit is uncommon in SSA. Patients in the
study benefited from measurement of serum creatinine,
a test not routinely performed at QECH in obstetric pa-
tients outside of research studies, and rarely available in
any patient elsewhere in Malawi. Those with elevated
creatinine benefitted from management from specialist
renal services. As such, the study is likely to underesti-
mate AKI severity and overestimate renal recovery.
Interpretation
Overall, fetal outcomes were poor. The World Health
Organisation reports the 2010 Malawi perinatal mortal-
ity rate to be 4% [19], which is significantly lower than
the 13.8% in this study. Moreover, our narrower defin-
ition of perinatal mortality (only following neonates to
discharge) likely underestimates the true value. Poor
fetal outcomes might partly be accounted for by the re-
cruitment of women with acute illness and preeclampsia
itself may also play a role, given the majority of partici-
pants (n = 164; 54.3%) were recruited with this risk fac-
tor for AKI.
Preeclampsia is known to be a significant cause of ob-
stetric AKI in developed and developing countries. A
French ICU study reported 28% (24/85) of admissions
with eclampsia, HELLP or preeclampsia without HELLP
developed AKI [20]. A study from Cameroon found
18.5% (10/54) of admissions with severe preeclampsia
and eclampsia had AKI on day-1 post-partum [11]. Our
study supports these findings, reporting a significant
Table 4 Conditions contributing to the development of AKI in
this study, compared to National Canadian data for 2007–10 [5]





Mehrabadi et al. [5]
Antepartum haemorrhage 4 (15.4) 13 (4.5)
Postpartum haemorrhage 2 (7.7) 91 (31.4)
Gestational hypertension 2 (7.7) 37 (12.7)
Preeclampsia 14 (53.8) 120 (41.4)
Eclampsia 4 (15.4) 10 (3.5)
Sepsis 4 (15.4) 36 (12.4)
Cardiac failure 1 (3.8) 21 (7.2)
Multiple conditions are present in some patients. Canadian data from:
Mehrabadi et al. [5]
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association between preeclampsia spectrum and AKI;
12.2% women recruited with preeclampsia spectrum had
AKI. We feel this is of relevance to settings across SSA
where preeclamptic patients present to healthcare facil-
ities that often lack the capability to diagnose AKI. In-
deed, given the inclusion of less severe cases of
preeclampsia in our study compared to those cited
above, the burden of preeclampsia-related AKI is rela-
tively high.
Reasons for the prevalence of preeclampsia and its as-
sociated poor outcomes include: late antenatal booking
visits; infrequent antenatal care; limited access to routine
antenatal ultrasound; minimal use of aspirin prophylaxis;
and delivery of antenatal care by non medically trained
health care workers. Poor access to diagnostics for and
interpretation of blood pressure and proteinuria meant
most preeclampsia was diagnosed when symptomatic,
thus advanced and more severe in nature. Additionally,
recent data demonstrate pre-pregnancy recovered AKI is
a risk factor for subsequent preeclampsia and poor fetal
outcomes [21]. In a country where AKI is common and
severe [18], previous recovered AKI may be a significant
contributor to the preeclampsia burden; the interaction
of recovered AKI, preeclampsia, and poor fetal outcomes
provides an important avenue of future study.
We feel improving diagnosis and treatment of pre-
eclampsia is key to preventing AKI, and moreover, im-
proving fetal outcomes in Malawi. In a multigravid
population, preventing repeated cycles of preeclampsia-
related AKI might in turn reduce the incidence of CKD.
Better antenatal care is key to reducing the burden of
preeclampsia and this will require increased provision of
trained healthcare workers, better access to diagnostics
including the development of simple point-of-care tests
to detect kidney disease in rural settings [22], and
population-level education regarding early presentation
to antenatal care.
Conclusions
The incidence of obstetric AKI in Malawi is significantly
greater than in developed countries and this study pro-
vides novel and important data for obstetricians, ne-
phrologists and governments in the provision of
healthcare. The majority of AKI was caused by pre-
eclampsia, a potentially detectable and treatable disease
which is also likely to underlie much of the perinatal
mortality identified. Poor fetal outcomes reflect the chal-
lenges of antenatal and perinatal care in Malawi. Future
work should investigate obstetric AKI and preeclampsia
in health centres and district hospitals, where facilities
and staffing are poorer, and address whether improved
recognition and treatment of preeclampsia can reduce
the incidence of AKI and improve fetal outcomes in this
part of the world.
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